Compare Agilent Technologies Inc (A) vs Incyte Corporation (INCY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Agilent Technologies Inc vs Incyte Corporation — how do they compare? Agilent Technologies Inc trades at $148.72 (market cap $42.22B), while Incyte Corporation trades at $120.45 (market cap $24.54B). The key difference: Agilent Technologies Inc is the larger of the two by market cap, and Agilent Technologies Inc pays a 0.68% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals.
| A | INCY | |
|---|---|---|
Market Cap | $42.22B | $24.54B |
Sector | Health | Health |
52-Week High | $157.20 | $129.93 |
52-Week Low | $110.24 | $81.61 |
Enterprise Value | $43.77B | $20.04B |
Dividend Yield | 0.68% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Agilent Technologies Inc
Originally spun out of Hewlett-Packard in 1999, Agilent has evolved into a leading life sciences and diagnostics firm. Today, Agilent's measurement technologies serve a broad base of customers with its three operating segments: life science and applied tools (45% of fiscal 2021 sales), cross lab (35% of sales consisting of consumables and services related to its life science and applied tools), and diagnostics and genomics (20%). Over half of its sales are generated from the biopharmaceutical, chemical, and energy end markets, but it also supports clinical lab, environmental, forensics, food, academic, and government-related organizations. The company is geographically diverse, with operations in the U.S. (34%) and China (20%) representing the largest country concentrations.
Read more on A →About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →
